Description
Asciminib
Each LuciAsc tablet contains: 43.24mg Asciminib HCL equivalent to Asciminib … 40mg
INDICATION
LuciAsc is a kinase inhibitor indicated for the treatment of adult patients with: • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). Ph+ CML in CP Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.
DOSAGE AND USE
Recommended Dosage in Ph+ CML in CP: 80 mg orally once daily or 40 mg twice daily. Recommended Dosage in Ph+ CML in CP with the T315I Mutation: 200 mg orally twice daily. Avoid food for at least 2 hours before and 1 hour after taking LuciAsc. Tablet should be swallowed whole & not chewed or crushed.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administered LuciAsc in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.